Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27538428 | 1.00 | CNR1 (0.41) | CNR1CNR2CA2CA12CA1 | |
| SCHEMBL5225484 | 0.86 | CNR1 (0.44) | CNR1CNR2 | |
| Ammonia Solution, Strong SCHEMBL5224597 | 0.85 | CNR1 (0.43) | CNR1CNR2 | |
| SCHEMBL10144788 | 0.81 | CNR1 (0.45) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL11492383 | 0.80 | CNR1 (0.44) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL11490445 | 0.80 | CNR1 (0.44) | CNR1CNR2MMP2 | |
| SCHEMBL13944848 | 0.78 | NAAA (0.47) | CNR1CNR2 | |
| SCHEMBL2942452 | 0.76 | CNR1 (0.37) | CNR1CNR2SRCENPEP | |
| SCHEMBL2942451 | 0.76 | CNR1 (0.37) | CNR1CNR2SRCENPEP | |
| SCHEMBL11480826 | 0.76 | HPGD (0.46) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0804431-B9 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 2003-01-02 | — | — | EP | claimed |
| EP-0804431-B1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 2002-07-24 | — | — | EP | claimed |
| EP-1427423-B9 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2017-12-20 | — | — | EP | disclosed |
| EP-2182088-B1 | Atomic layer deposition using metal amidinates | HARVARD COLLEGE (US) | 2013-07-17 | — | — | EP | disclosed |
| US-8455672-B2 | Atomic layer deposition using metal amidinates | PRESIDENT AND FELLOWS OF HARVARD (US) | 2013-06-04 | — | — | US | disclosed |
| EP-2032529-B1 | METAL(IV) TETRA-AMIDINATE COMPOUNDS AND THEIR USE IN VAPOR DEPOSITION | HARVARD COLLEGE (US) | 2012-10-17 | — | — | EP | disclosed |
| US-7737290-B2 | Atomic layer deposition using metal amidinates | PRESIDENT AND FELLOWS OF HARVARD UNIVERSITY (US) | 2010-06-15 | — | — | US | disclosed |
| EP-2182088-A1 | Atomic layer deposition using metal amidinates | President and Fellows of Harvard College (US) | 2010-05-05 | — | — | EP | disclosed |
| US-20100092667-A1 | ATOMIC LAYER DEPOSITION USING METAL AMIDINATES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-04-15 | — | — | US | disclosed |
| EP-1563117-B1 | ATOMIC LAYER DEPOSITION USING METAL AMIDINATES | HARVARD COLLEGE (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-1427713-B1 | BENZOTHIAZEPINE DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDEMIA | ALBIREO AB (SE) | 2010-01-06 | — | — | EP | disclosed |
| EP-1427713-A1 | BENZOTHIAZEPINE DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDEMIA | Astrazeneca AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2004046417-A2 | ATOMIC LAYER DEPOSITION USING METAL AMIDINATES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040067933-A1 | Chemical compounds | ELOBIX AB (SE) | 2004-04-08 | — | — | US | disclosed |
| CN-1481373-A | 1,5-benzothiazepines compounds and its use as antilipemic agent | — | 2004-03-10 | — | — | CN | disclosed |
| WO-2004005247-A1 | DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| EP-1345918-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2003022825-A1 | BENZOTHIAZEPINE DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDEMIA | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003022830-A1 | BENZOTHIEPINE ILEAL BILE ACID TRANSPORT INHIBITORS | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | disclosed |
| WO-2002050051-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092667-A1 | ATOMIC LAYER DEPOSITION USING METAL AMIDINATES | NIT2, SLC9B2, NOS2 | CNR1 4549/4885CNR2 3995/4885CA2 377/4885 |
| US-20040067933-A1 | Chemical compounds | SLC10A2, SLC10A1, ABCB11 | CNR1 2016/4885CNR2 2161/4885CA2 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.